It is known that the limited efficacy of PD‐1/PD‐L1 ICB therapy may result from the activation of other ICP pathways.[7] We therefore hypothesized that the expression profile of HLA‐G on NSCLC tumor cells would be affected following treatment with PD‐L1 blocking antibodies, and vice versa. This evidence concerns the gene HLA-G and non-small cell lung carcinoma.